BGB-43395-302: An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease

Objective

Clinical Trial Details

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Contact
Gynecology Breast Coordinators at 605-322-7536
or gyn.breastresearch@avera.org

Location

  • Avera Cancer Institute — Mitchell
    605 N Foster St
    Mitchell, SD 57301
    Main: 605-995-5756
  • Avera Cancer Institute — Sioux Falls
    1000 E 23rd St
    Suite 340
    Sioux Falls, SD 57105
    Main: 605-322-3000
  • Avera Cancer Institute — Aberdeen
    310 S Penn St
    Suite 106
    Aberdeen, SD 57401
    Main: 605-622-8700
  • Avera Cancer Institute — Marshall
    300 S Bruce St
    Marshall, MN 56258
    Main: 507-537-9000
  • Avera Cancer Institute — Pierre
    801 E Sioux Ave
    Pierre, SD 57501
    Main: 605-224-3370